A prospective study on chemotherapy-induced hepatitis B virus reactivation in chronic HBs Ag carriers with hematologic malignancies and pre-emptive therapy with nucleoside analogues

Yagci M., Acar K., Sucak G. T., Aki Z., Bozdayi G., Haznedar R.

LEUKEMIA & LYMPHOMA, vol.47, no.8, pp.1608-1612, 2006 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 47 Issue: 8
  • Publication Date: 2006
  • Doi Number: 10.1080/10428190500472974
  • Journal Name: LEUKEMIA & LYMPHOMA
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED)
  • Page Numbers: pp.1608-1612
  • Keywords: hematologic malignancy, chronic lymphocytic leukemia, chemotherapy, hepatitis B virus reactivation, prophylaxis, treatment, NON-HODGKINS-LYMPHOMA, CYTOTOXIC CHEMOTHERAPY, LAMIVUDINE THERAPY, CANCER-PATIENTS, RISK-FACTORS, TRANSPLANTATION, PROPHYLAXIS, PREVENTION, INFECTION, JAPAN
  • Gazi University Affiliated: Yes


Chemotherapy-induced hepatitis B virus (HBV) reactivation is a serious problem in chronic HBV carriers with hematologic malignancies. In 12 patients with hematologic malignancies, we performed a prospective study to determine the effectiveness of nucleoside analogues in the pre-emptive therapy of chemotherapy-induced HBV reactivation. HBV reactivation occurred in seven patients (58.3%) whereas five of the seven patients (71%) responded to nucleoside analogue therapy. HBV reactivation-related acute liver failure and death was not observed in the present study. All five patients with chronic lymphocytic leukemia (CLL) experienced chemotherapy-induced HBV reactivation regardless of the chemotherapy regimen. Therefore, we suggest that CLL carries a significant risk of chemotherapy-induced HBV reactivation. The pre-emptive therapy of chemotherapy-induced HBV reactivation appears to be safe, based on the results of this pilot study. Pre-emptive therapy enables the definition of high-risk patients who cannot be identified by primary prophylaxis.